CH0363463438
© Globe Newswire
10.12.2025
IDIA
LISTED
SIX
New Hypertension publication underscores aprocitentan’s potential in managing hypertension patients with CKD
News Preview
Allschwil, Switzerland – December 10, 2025Idorsia Ltd (SIX: IDIA) announced the publication of a new analysis from the landmark Phase 3 PRECISION study in Hypertension titled “Aprocitentan in Patients with Chronic Kidney Disease and Resistant Hypertension”.1 The analysis examined the efficacy and safety of aprocitentan (TRYVIO™/JERAYGO™) in patient...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
IDIA
LISTED
SIX
Idorsia’s treatment for insomnia disorder wins the inaugural Prix Galien Bridges Award in the ‘Best Biotechnology & Pharmaceutical Product’ category
News Preview
Allschwil, Switzerland – December 9, 2025Idorsia Ltd (SIX: IDIA) announces that its novel treatment for insomnia disorder has been awarded the inaugural Prix Galien Bridges Award in the category of “Best Biotechnology & Pharmaceutical Product”. The award recognizes groundbreaking medicines, including biologics, gene therapies, and traditional p...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.10.2025
IDIA
LISTED
SIX
QUVIVIQ sales up >130% driving Idorsia toward profitability – 9M 2025 results
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
10.10.2025
IDIA
LISTED
SIX
Idorsia successfully completes an upsized offering of shares – funding the company to overall profitability
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
09.10.2025
IDIA
LISTED
SIX
Idorsia launches an offering of registered shares – to fund the company to overall profitability
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
IDIA
LISTED
SIX
Global expansion of Idorsia’s QUVIVIQ continues as Simcere launches in China
News Preview
Allschwil, Switzerland – September 22, 2025Idorsia Ltd. (SIX: IDIA) announces that Simcere Pharmaceuticals Group Ltd (2096.HK, “Simcere”) has launched QUVIVIQ® (daridorexant) in China. QUVIVIQ, Idorsia’s dual orexin receptor antagonist, is indicated for the treatment of adult patients with insomnia characterized by difficulty falling asleep and/or...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
IDIA
LISTED
SIX
Idorsia’s JERAYGO (aprocitentan) approved in Switzerland for the treatment of resistant hypertension
News Preview
Allschwil, Switzerland – September 19, 2025Idorsia Ltd (SIX: IDIA) announces that Swissmedic has granted marketing authorization for JERAYGO™ (aprocitentan) for the treatment of resistant hypertension in adult patients in combination with at least three antihypertensive medicinal products.1 The recommended dose is 12.5 mg orally once daily. The dos...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.09.2025
IDIA
LISTED
SIX
Idorsia shares new analyses of daridorexant for patients with insomnia at World Sleep 2025
News Preview
Allschwil, Switzerland – September 10, 2025Idorsia Ltd (SIX: IDIA) shares new analyses of daridorexant for patients with insomnia and further characterizes insomnia disorder at World Sleep 2025, delivering on its ongoing commitment to further the science of sleep and insomnia....
Themefolio
Profiler
Peergroup
© PR Newswire
05.09.2025
IDIA
LISTED
SIX
Idorsia to collaborate with two leading academic medical centers to launch IMPACT-HTN - a US initiative to transform care for patients with difficult-to-control hypertension
News Preview
Multi-phase program to standardize treatment, generate real-world evidence, and explore AI-powered tools to improve outcomes for hypertension patientsALLSCHWIL, Switzerland and RADNOR, Pa., Sept. 5, 2025 /PRNewswire/ -- Idorsia Ltd (SIX: IDIA) announces a first-of-its-kind initiative with the Stanford Hypertension Center and Duke Heart Center to...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.09.2025
IDIA
LISTED
SIX
Idorsia to collaborate with two leading academic medical centers to launch IMPACT-HTN – a US initiative to transform care for patients with difficult-to-control hypertension
News Preview
Allschwil, Switzerland & Radnor, Philadelphia – September 5, 2025Idorsia Ltd (SIX: IDIA) announces a first-of-its-kind initiative with the Stanford Hypertension Center and Duke Heart Center to launch IMPACT-HTN, a new three-phase program to transform and modernize the management of difficult-to-control hypertension. Patients requiring multiple...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.08.2025
IDIA
LISTED
SIX
Idorsia’s TRYVIO – First FDA-approved therapy to target the endothelin pathway for systemic hypertension
News Preview
Allschwil, Switzerland – August 28, 2025Idorsia Ltd (SIX: IDIA) releases an OnDemand investor webcast outlining how TRYVIO™ (aprocitentan) – the first and only hypertension therapy targeting the endothelin pathway – fits into the treatment landscape for difficult-to-control hypertension. In addition, the company will host a live investor Q&A on...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.08.2025
IDIA
LISTED
SIX
Idorsia successfully completes convertible bonds restructuring
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
19.08.2025
IDIA
LISTED
SIX
Idorsia publishes end results of repurchase offer for its 2025 and 2028 convertible bonds
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.08.2025
IDIA
LISTED
SIX
TRYVIO nominated for the 2025 Prix Galien USA “Best Pharmaceutical Product”
News Preview
Allschwil, Switzerland – August 12, 2025Idorsia Ltd (SIX: IDIA) announced today that The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, has nominated TRYVIO™ (aprocitentan) in the category of “Best Pharmaceutical Product” in the 2025 Prix Galien USA awards. The winner will be announced during th...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.08.2025
IDIA
LISTED
SIX
Idorsia publishes interim results of repurchase offer for its 2025 and 2028 convertible bonds
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.07.2025
IDIA
LISTED
SIX
Invitation to Idorsia's HY 2025 Financial Reporting webcast and conference call with our new CEO Srishti Gupta
News Preview
Idorsia will publish its Half Year 2025 Financial Reporting on Wednesday July 30, at 07:00 CEST....
Themefolio
Profiler
Peergroup
© Globe Newswire
30.06.2025
IDIA
LISTED
SIX
A factory in a lab: Idorsia's breakthrough synthetic glycan vaccine platform validated for the first time in humans
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.06.2025
IDIA
LISTED
SIX
Bondholders approve amended terms of the 2025 and 2028 convertible bonds
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.06.2025
IDIA
LISTED
SIX
Idorsia launches repurchase offer for its 2025 and 2028 convertible bonds
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.06.2025
IDIA
LISTED
SIX
Idorsia’s QUVIVIQ expands into China as Simcere receives NDA approval – Idorsia and Simcere update their licensing agreement
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.06.2025
IDIA
LISTED
SIX
Idorsia announces the appointment of Srishti Gupta, MD as CEO to ensure the long-term success of Idorsia
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.06.2025
IDIA
LISTED
SIX
Idorsia publishes invitations to bondholder meetings
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.05.2025
IDIA
LISTED
SIX
Shareholders vote in favor of all proposals by the Board at Idorsia’s Annual General Meeting 2025
News Preview
Allschwil, Switzerland – May 28, 2025At today’s Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Basel, Switzerland, shareholders voted convincingly in favor of all proposals by the Board of Directors....
Themefolio
Profiler
Peergroup
© Globe Newswire
21.05.2025
IDIA
LISTED
SIX
New funds secured – allowing the commercial ramp-up of QUVIVIQ to accelerate Idorsia’s path to profitability
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.05.2025
IDIA
LISTED
SIX
Idorsia issues invitation to the 2025 Annual General Meeting of Shareholders
News Preview
Allschwil, Switzerland – May 2, 2025Idorsia Ltd (SIX: IDIA) today issued the invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The meeting to approve the Annual Report of the year ending December 31, 2024, will be held on Wednesday, May 28, 2025, at 09.00 CEST at the Congress Center, Messe...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.04.2025
IDIA
LISTED
SIX
Higher cantonal composition authority approved the amendments to the terms of the 2025 convertible bond
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.04.2025
IDIA
LISTED
SIX
The effect of aprocitentan for reducing blood pressure and proteinuria in Black patients with resistant hypertension published in Hypertension
News Preview
Allschwil, Switzerland – April 9, 2025Idorsia Ltd (SIX: IDIA) today announced the publication of "Aprocitentan for Blood Pressure Reduction in Black Patients” in the April edition of Hypertension1. The publication reports preplanned analyses of the efficacy, tolerability and safety of aprocitentan – Idorsia’s once-daily, orally active, dual endothe...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.04.2025
IDIA
LISTED
SIX
US FDA approves an updated label for TRYVIO (aprocitentan) removing the REMS requirement
News Preview
Allschwil, Switzerland – April 9, 2025Idorsia Ltd (SIX: IDIA) today announced that the US Food & Drug Administration (FDA), after having released TRYVIO from its REMS (Risk Evaluation and Mitigation Strategy) requirement (announced on March 17, 2025), has now approved the updated label for TRYVIO™ (aprocitentan). TRYVIO is Idorsia’s dual endoth...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.03.2025
IDIA
LISTED
SIX
Idorsia publishes its Annual Report 2024
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.03.2025
IDIA
LISTED
SIX
US FDA removes REMS requirement for TRYVIO (aprocitentan) – minimizing the burden on the healthcare delivery systems and patients
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.03.2025
IDIA
LISTED
SIX
Idorsia announces the publication of positive data with daridorexant in patients with chronic insomnia and nocturia
News Preview
Allschwil, Switzerland – March 14, 2025Idorsia Ltd (SIX: IDIA) today announced the publication of “A randomized cross-over trial of daridorexant for the treatment of chronic insomnia and nocturia” in the Journal of Sleep Research.The new data provides evidence of the benefit of Idorsia’s dual orexin receptor antagonist, daridorexant (QUVIVIQ™), at...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.03.2025
IDIA
LISTED
SIX
Idorsia announces financial results for 2024
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.02.2025
IDIA
LISTED
SIX
Invitation to Idorsia's Full Year 2024 Financial Reporting webcast and conference call
News Preview
Idorsia will publish its Full Year 2024 Financial Reporting on Tuesday March 4, 2025, at 07:00 CET....
Themefolio
Profiler
Peergroup
© Globe Newswire
26.02.2025
IDIA
LISTED
SIX
Idorsia reaches an agreement with significant bondholders to restructure its convertible bond debt and to secure funding for future operations
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.02.2025
IDIA
LISTED
SIX
Idorsia and Viatris update their collaboration for selatogrel and cenerimod
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.02.2025
IDIA
LISTED
SIX
Idorsia is released from exclusivity constraint regarding the global rights to aprocitentan – now pivoting to alternative parties
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.02.2025
IDIA
LISTED
SIX
Bondholders approve amended terms of the 2025 convertible bonds
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.02.2025
IDIA
LISTED
SIX
Idorsia publishes the resolutions for the upcoming bondholder meeting
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.01.2025
IDIA
LISTED
SIX
Idorsia presents at J.P. Morgan Healthcare Conference 2025 – fighting to create value for all stakeholders
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.01.2025
IDIA
LISTED
SIX
Idorsia publishes an invitation to a bondholder meeting
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.01.2025
IDIA
LISTED
SIX
Idorsia to call for a bondholder meeting
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.12.2024
IDIA
LISTED
SIX
Idorsia provides update on the exclusive negotiations for the global rights to aprocitentan
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.11.2024
IDIA
LISTED
SIX
Idorsia enters into exclusive negotiations for global rights to aprocitentan
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.11.2024
IDIA
LISTED
SIX
Idorsia is advancing the treatment of hypertension with new data at the 2024 American Heart Association (AHA) Scientific Sessions
News Preview
Allschwil, Switzerland – November 11, 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.10.2024
IDIA
LISTED
SIX
Idorsia announces financial results for the first nine months of 2024
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.10.2024
IDIA
LISTED
SIX
New data on aprocitentan to be presented at the ASN Kidney Week 2024
News Preview
Allschwil, Switzerland – October 16, 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.07.2024
IDIA
LISTED
SIX
Idorsia announces financial results for the first half 2024
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.07.2024
IDIA
LISTED
SIX
Invitation to Idorsia's Half Year 2024 Financial Reporting webcast and conference call
News Preview
Idorsia will publish its Half Year 2024 Financial Reporting on Thursday July 25, 2024, at 07:00 CEST....
Themefolio
Profiler
Peergroup
© Globe Newswire
01.07.2024
IDIA
LISTED
SIX
Idorsia’s JERAYGO (aprocitentan) approved in Europe as first and only ERA for the treatment of resistant hypertension
News Preview
Allschwil, Switzerland – July 1, 2024Idorsia Ltd (SIX: IDIA) announced today that the European Commission (EC) has approved JERAYGO™ (aprocitentan) for the treatment of resistant hypertension in adult patients in combination with at least three antihypertensive medicinal products.1 The recommended dose is 12.5 mg orally once daily. The dose can be...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.06.2024
IDIA
LISTED
SIX
Higher cantonal composition authority issues written court decision in respect to the amendments to the terms of the 2024 convertible bonds
News Preview
Allschwil, Switzerland – June 28, 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.06.2024
IDIA
LISTED
SIX
Higher cantonal composition authority approved the amendments to the terms of the 2024 convertible bonds
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.06.2024
IDIA
LISTED
SIX
Idorsia’s novel treatment for chronic insomnia wins the prestigious Prix Galien Suisse 2024 innovation award in the ‘Primary & Speciality’ category
News Preview
Allschwil, Switzerland – June 21, 2024Idorsia Ltd (SIX: IDIA) announced today that its novel treatment for chronic insomnia has been awarded the prestigious Prix Galien Suisse 2024 innovation prize in the ‘Primary & Speciality’ category. The Prix Galien Suisse is awarded annually to the most innovative new medicines and diagnostics on the Swiss...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.06.2024
IDIA
LISTED
SIX
Idorsia holds its Annual General Meeting of Shareholders
News Preview
Allschwil, Switzerland – June 13, 2024At today’s Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Basel, Switzerland, shareholders voted in favor of all proposals by the Board of Directors with very large majorities....
Themefolio
Profiler
Peergroup
© Globe Newswire
03.06.2024
IDIA
LISTED
SIX
New data with daridorexant to be presented at SLEEP 2024
News Preview
Allschwil, Switzerland – June 3, 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.05.2024
IDIA
LISTED
SIX
Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024
News Preview
Allschwil, Switzerland – May 31, 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.05.2024
IDIA
LISTED
SIX
Idorsia issues invitation to the 2024 Annual General Meeting of Shareholders
News Preview
Allschwil, Switzerland – May 23, 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.05.2024
IDIA
LISTED
SIX
Idorsia announces changes to Idorsia Executive Committee and Board of Directors
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.05.2024
IDIA
LISTED
SIX
Idorsia announces financial results for the first quarter 2024 – advancing the company with renewed vigor
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.05.2024
IDIA
LISTED
SIX
Idorsia announces financial results for the full year of 2023 – Adapting the company to create sustainable value
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.05.2024
IDIA
LISTED
SIX
Bondholders approve amended terms of the 2024 convertible bonds
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
